PT Journal
AU Klapper, W
   Hoster, E
   Determann, O
   Oschlies, I
   van der Laak, J
   Berger, F
   Bernd, HW
   Cabeçadas, J
   Campo, E
   Cogliatti, S
   Hansmann, ML
   Kluin, PM
   Kodet, R
   Krivolapov, YA
   Loddenkemper, C
   Stein, H
   Möller, P
   Barth, TEF
   Müller-Hermelink, K
   Rosenwald, A
   Ott, G
   Pileri, S
   Ralfkiaer, E
   Rymkiewicz, G
   van Krieken, JH
   Wacker, HH
   Unterhalt, M
   Hiddemann, W
   Dreyling, M
TI Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network
SO Journal of hematopathology
PY 2009
BP 103
EP 111
VL 2
IS 2
PU Springer Science and Business Media LLC
DI 10.1007/s12308-009-0036-x
WP https://macau.uni-kiel.de/receive/macau_mods_00002119
LA en
SN 1868-9256
AB Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive lymphoma cells on histopathological slides, has been shown to be a very powerful prognostic biomarker. The pathology panel of the European MCL Network evaluated methods to assess the Ki-67 index including stringent counting, digital image analysis, and estimation by eyeballing. Counting of 2 × 500 lymphoma cells is the gold standard to assess the Ki-67 index since this value has been shown to predict survival in prospective randomized trials of the European MCL Network. Estimation by eyeballing and digital image analysis showed a poor concordance with the gold standard (concordance correlation coefficients [CCC] between 0.29 and 0.61 for eyeballing and CCC of 0.24 and 0.37 for two methods of digital image analysis, respectively). Counting a reduced number of lymphoma cells (2 × 100 cells) showed high interobserver agreement (CCC = 0.74). Pitfalls of the Ki-67 index are discussed and guidelines and recommendations for assessing the Ki-67 index in MCL are given.
PI Berlin
ER